Fate Therapeutics (FATE) PT Raised to $116 at Piper Sandler Ahead of Numerous Catalysts
Tweet Send to a Friend
Piper Sandler analyst Edward A. Tenthoff raised the price target on Fate Therapeutics (NASDAQ: FATE) to $116.00 (from $99.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
